These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 22817698)

  • 1. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.
    Byrski T; Dent R; Blecharz P; Foszczynska-Kloda M; Gronwald J; Huzarski T; Cybulski C; Marczyk E; Chrzan R; Eisen A; Lubinski J; Narod SA
    Breast Cancer Res; 2012 Jul; 14(4):R110. PubMed ID: 22817698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a phase II open-label, nonrandomized trial of oral satraplatin in patients with metastatic breast cancer.
    Smith JW; McIntyre KJ; Acevedo PV; Encarnacion CA; Tedesco KL; Wang Y; Asmar L; O'Shaughnessy JA
    Breast Cancer Res Treat; 2009 Nov; 118(2):361-7. PubMed ID: 19459042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
    Silver DP; Richardson AL; Eklund AC; Wang ZC; Szallasi Z; Li Q; Juul N; Leong CO; Calogrias D; Buraimoh A; Fatima A; Gelman RS; Ryan PD; Tung NM; De Nicolo A; Ganesan S; Miron A; Colin C; Sgroi DC; Ellisen LW; Winer EP; Garber JE
    J Clin Oncol; 2010 Mar; 28(7):1145-53. PubMed ID: 20100965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
    Park YH; Kim TY; Kim GM; Kang SY; Park IH; Kim JH; Lee KE; Ahn HK; Lee MH; Kim HJ; Kim HJ; Lee JI; Koh SJ; Kim JY; Lee KH; Sohn J; Kim SB; Ahn JS; Im YH; Jung KH; Im SA;
    Lancet Oncol; 2019 Dec; 20(12):1750-1759. PubMed ID: 31668850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
    Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
    Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin-ifosfamide combination chemotherapy in metastatic triple-negative, anthracycline- and taxane-pretreated breast cancer patients; a phase II study.
    Halim A; Wahba H
    J BUON; 2012; 17(2):254-8. PubMed ID: 22740202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
    Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
    Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
    Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
    Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
    Rodler ET; Kurland BF; Griffin M; Gralow JR; Porter P; Yeh RF; Gadi VK; Guenthoer J; Beumer JH; Korde L; Strychor S; Kiesel BF; Linden HM; Thompson JA; Swisher E; Chai X; Shepherd S; Giranda V; Specht JM
    Clin Cancer Res; 2016 Jun; 22(12):2855-64. PubMed ID: 26801247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients.
    Ozdemir N; Aksoy S; Sendur MA; Akinci MB; Yazici O; Budakoglu B; Abali H; Oksuzoglu B; Zengin N
    J BUON; 2013; 18(4):831-7. PubMed ID: 24344005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly paclitaxel-cisplatin administration with G-CSF support in advanced breast cancer. A phase II study.
    Frasci G; Comella P; D'Aiuto G; Budillon A; Barbarulo D; Thomas R; Capasso I; Casaretti R; Daponte A; Caponigro F; Gravina A; Maiorino L; Caratení G; Gentile A; Comella G
    Breast Cancer Res Treat; 1998 May; 49(1):13-26. PubMed ID: 9694607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer.
    Farhat FS; Temraz S; Kattan J; Ibrahim K; Bitar N; Haddad N; Jalloul R; Hatoum HA; Nsouli G; Shamseddine AI
    Clin Breast Cancer; 2011 Dec; 11(6):384-9. PubMed ID: 21993011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
    Prat A; Saura C; Pascual T; Hernando C; Muñoz M; Paré L; González Farré B; Fernández PL; Galván P; Chic N; González Farré X; Oliveira M; Gil-Gil M; Arumi M; Ferrer N; Montaño A; Izarzugaza Y; Llombart-Cussac A; Bratos R; González Santiago S; Martínez E; Hoyos S; Rojas B; Virizuela JA; Ortega V; López R; Céliz P; Ciruelos E; Villagrasa P; Gavilá J
    Lancet Oncol; 2020 Jan; 21(1):33-43. PubMed ID: 31838010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results From the First Multicenter, Open-label, Phase IIIb Study Investigating the Combination of Pertuzumab With Subcutaneous Trastuzumab and a Taxane in Patients With HER2-positive Metastatic Breast Cancer (SAPPHIRE).
    Woodward N; De Boer RH; Redfern A; White M; Young J; Truman M; Beith J
    Clin Breast Cancer; 2019 Jun; 19(3):216-224. PubMed ID: 30922805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
    Pegram MD; Lipton A; Hayes DF; Weber BL; Baselga JM; Tripathy D; Baly D; Baughman SA; Twaddell T; Glaspy JA; Slamon DJ
    J Clin Oncol; 1998 Aug; 16(8):2659-71. PubMed ID: 9704716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR
    Musolino A; Campone M; Neven P; Denduluri N; Barrios CH; Cortes J; Blackwell K; Soliman H; Kahan Z; Bonnefoi H; Squires M; Zhang Y; Deudon S; Shi MM; André F
    Breast Cancer Res; 2017 Feb; 19(1):18. PubMed ID: 28183331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
    Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
    Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.